Abstract

The present study was designed to evaluate the effects of three non-steroidal anti-inflammatory drugs (NSAIDs) with varying cyclooxygenase selectivities on the small intestinal biochemical composition, function and histology during 1, 2-dimethylhydrazine (DMH) administration. Sprague Dawley male rats were divided into five different groups viz: Group 1 (control, vehicle treated), Group 2 (DMH-treated, 30 mg/kg body weight/week in 1 mM EDTA-saline, subcutaneously), Group 3 (DMH + aspirin-60 mg/kg body weight), Group 4 (DMH + celecoxib-6 mg/kg body weight), Group 5 (DMH + etoricoxib-0.64 mg/kg body weight). After six weeks of treatment, brush border membrane was isolated from the jejunum segment of all the groups and changes in the associated enzymes such as sucrase, lactase, maltase, alkaline phosphatase, membrane lipid composition, fluorescence polarizations of diphenylhexatriene, pyrene excimer formation, histological changes and surface characteristics were studied. The results indicated a significant alteration in the enzyme activity as well as changes in the structure and function of the intestine in the presence of the pro-carcinogen, DMH, which suggests the possible chemopreventive efficacy of NSAIDs against the intestinal cancer.

Introduction

The non-steroidal anti-inflammatory drugs (NSAIDs) are a group of drugs that relieve pain and inflammation and have also shown in recent times to prevent the formation of cancer in the different tissues including intestine. The chemopreventive efficacy of NSAIDs against colorectal cancer has particularly been well studied. Also, NSAIDs may decrease the incidence of carcinomas of the esophagus, stomach, breast, lung, prostate, urinary bladder and ovary. However, till date the clinical use of these agents is limited only to patients with familial adenomatous polyposis (FAP) a form of intestinal cancer, which may benefit from the chemopreventive treatment with the selective cyclooxygenase (COX) inhibitors.

However, NSAIDs are also associated with tissue toxicities such as gastrointestinal ulcers, bleeding and sometimes gastric perforation due to deep ulceration. These toxicities hampered the long-term use of classical NSAIDs for chemoprevention as they preferentially inhibit COX-1, and thereby remove the cytoprotective function of the prostaglandins in the intestinal mucosa. Gastrointestinal toxicities due to aspirin have been suggested by various reports. Thus, selective COX-2 inhibitors (celecoxib and etoricoxib) may become more effective and safer chemopreventive agents which spare the COX-1 and thereby the intestinal toxicity is prevented. However, before being accepted for clinical use, these drugs need to be further evaluated for membrane damage and related structural changes. One of the targets of such damage could be the intestinal brush border membrane (BBM) which is crucial for the digestion and absorption of the end-product nutrients. The BBM is involved in digestion due to the presence of disaccharidases, alkaline phosphatase, dipeptidases, enterokinases, etc. and also a number of specific protein mediated transport processes.

The BBM comes into direct contact with the material present in the intestine to be absorbed and thus, is most likely to be affected by the drugs. One important way such drug-membrane interaction can be studied is by looking with the steady state fluorescence polarization and anisotropy with the membrane labelled with the apolar probe, diphenylhexatriene. Further, the membrane fluidity which can be selectively perturbed by the drug can also be studied by quantifying the transitional diffusion of pyrene and its excimer formation in the membrane. Changes in the membrane lipid composition, particularly the phospholipids and cholesterol, and their ratio as studied here, are also important indicators of membrane fluidity.

Keeping in view this background, the molecular interaction of a carcinogenic agent like DMH and the chemopreventive ability of the NSAIDs in colon cancer can be extended, to small intestine to evaluate the effects of three NSAIDs i.e. aspirin (classical NSAID, inhibiting COX-1) celecoxib and etoricoxib (COX-2 selective inhibitors) and dimethylhydrazine on the small intestinal structures and functions. The results suggest certain indication of the molecular structure and composition of the membrane in the small intestine as to the refractoriness of this segment to the development of neoplastic growth, although the morphogenesis of chemically induced neoplasm had been described both in the colon as well as the small intestine.

Materials and methods

Animals and treatment

Male Sprague Dawley rats (170-210 g) were obtained from the central animal house of the Panjab University, Chandigarh. All the animals were kept in polyprene cages under hygienic conditions and supplied with pellet diet and drinking water ad libitum. Fifty rats were divided into five groups; Group 1 (control) received the vehicle of the drugs (1 mM EDTA- saline and 0.5% carboxymethyl cellulose, CMC), Group 2 (DMH treated) administered freshly prepared DMH (30 mg/kg body weight/week, subcutaneously), Group 3 DMH + a daily oral dose of aspirin – 60 mg/kg body weight, Group 4 DMH + a daily oral dose of celecoxib – 6 mg/kg body weight, Group 5 DMH + a daily oral dose of etoricoxib 0.64 mg/kg body weight. 1,2-dimethylhydrazine (DMH) was obtained from Sigma Chemical Co. (St. Louis, MO). DMH was prepared fresh every week immediately before the injection in 1 mM EDTA-saline, pH being adjusted to 7.0 using NaOH solution. NSAIDs were generously provided by Ranbaxy Research Laboratories (Gurgaon, India). After six weeks of treatment the animals were anaesthetized with ether and sacrificed quickly by decapitation. Animals were also weighed weekly till the termination of the treatment period. All of the animal procedures as reported here followed the guidelines approved by the Panjab University Ethical Committee on the use of the experimental animals for biomedical research.

Preparation of intestinal brush border membrane (BBM)

The BBM of rat intestine was isolated using the method of Schmitz et al. A known weight of jejunal portion of the intestine was flushed with ice-cold saline, minced and then homogenized in chilled 1 mM Tris – 50 mM mannitol buffer (pH-7.4) in a motor driven homogenizer at 4 °C. The 10% homogenate was passed through two layers of cheese cloth. To the above filtrate, anhydrous CaCl₂ was added with constant stirring (10 mM final conc.) on a magnetic stirrer and left for 10-15 min in cold. Later it was centrifuged at 2,000 × g for 10 min at 4 °C. The pellet thus obtained was discarded and the supernatant was recentrifuged at 42,000 g for 20 min. The supernatant obtained in the above step was discarded, while the pellet suspended in 20 vol of 50 mM sodium maleate buffer (pH 6.5-6.8) and recen-
trifuged at 42,000 × g for 20 min. The supernatant was again discarded and the pellet was suspended in 50 mM sodium maleate buffer (pH 6.5-6.8) containing 0.02% sodium azide (NaN₃). The final membrane obtained was similar to the P₂ fraction of Schmitz et al and used for various biochemical studies.

**Assay of disaccharidases**

The activity of sucrase, lactase and maltase were determined by the method of Dahlqvist¹⁴ by measuring the D-glucose liberated from the respective disaccharide sugar substrate using a glucose oxidase-peroxidase enzymatic system (GOD-POD).

**Assay of alkaline phosphatase**

Alkaline phosphatase activity was assayed according to the method of Bergmeyer¹⁵ by measuring the liberated inorganic phosphate from the phosphate monoester substrate, p-nitrophenyl phosphate.

**Protein estimation**

Protein concentration was determined by the method of Lees and Paxman¹⁶ by using Bovine serum albumin (BSA) as standard.

**Extraction of lipids**

Lipids were extracted from the BBM following the method of Folch et al.¹⁷ Membrane suspension (150-200 mg protein) was mixed in a flask with 20 vol of chloroform: methanol (2:1 v/v) and left for 15 min at 45 °C. The contents were mixed thoroughly and filtered through a Whatman No.1 filter paper into a graduated cylinder. The residue left on the filter paper was then washed three times with 10 ml of chloroform: methanol (2:1). Then, 0.2 vol KCl (0.9%) was added (20% of total volume) to the extract. The contents were mixed vigorously and allowed to stand in cold overnight so as to separate the aqueous and lipid layers distinct. Upper aqueous phase was removed with Pasteur pipette and the lower layer washed three times with 2 ml chloroform: methanol: 0.9% KCl, 3: 48:47 v/v. The washed lower volume was transferred to a round bottom flask and evaporated to dryness at a temp below 45 °C while the upper aqueous layer was added each time to the previously separated upper phase and used for the estimation of ganglioside-sialic acid. To the residue, 5 ml of chloroform: methanol: water, 64:32:4 v/v was added and evaporated to dryness. This was repeated three times. The dried lipid was redissolved in chloroform and filtered again. The filtrate was evaporated in a rotary evaporator under reduced pressure and at a temp slightly less than 45 °C. A known volume of chloroform: methanol (2:1 v/v) was added to redissolve the lipids in a tightly closed container and used as such for various lipid estimations.

**Estimation of total lipids**

Total lipids were estimated following the method of Fringes and Dunn¹⁸ measuring the coloured complex with a phosphate ester of vanillin (colouring reagent).

**Estimation of cholesterol**

Cholesterol level was measured by the method of Zlatkis et al.¹⁹ In the presence of H₂SO₄ and Glacial acetic acid, cholesterol forms a colored complex with FeCl₃, that can be measured colorimetrically at 540 nm.

**Estimation of phospholipid phosphorus**

Inorganic phosphorous estimation was done in the phospholipids after digestion with magnesium nitrate according to the method of Ames.²⁰

**Estimation of ganglioside-sialic acid**

Sialic acid was estimated by the method of Warren.²¹ Sialic acid (N acetyl neuraminic acid) is oxidized with sodium periodate in conc. orthophosphoric acid. The periodate oxidation product is coupled with thiobarbituric acid and resulting chromophore is extracted in cyclohexanone and optical density was read.

**Fluorescence studies with DPH**

The lipid-soluble fluorescent probe, 1, 6-Diphenyl-1, 3, 5-hexatriene (DPH) was used in the fluidity studies. For this a stock solution of 2 mM probe in tetrahydrofuran (THF) was prepared and stored being protected from light at room temp. Aqueous suspension of DPH was prepared freshly each time. A small volume of DPH solution in THF was injected with rapid stirring into 1,000 volumes of sodium maleate buffer at room temperature. The suspension was stirred for at least 2 h after which no odor of THF was detected and the suspension showed negligible fluorescence. In a typical experiment BBM (100-200 µg protein) were incubated in 2 ml of sodium maleate buffer containing 1 µM DPH suspension for 2-4 h at 37 °C. Thereafter, estimations of fluorescence intensity (F), fluorescence polarization (p) and fluorescence anisotropy (r) were made with an excitation wavelength of 365 nm and emission wavelength of 430 nm using a Perkin Elmer Luminescence Spectrometer LS 55. Anisotropy parameter [r/r -1]-1 was then calculated using r, value for DPH as 0.362.²² Also, the order parameter was calculated using the relationship S² = (4/3 r − 0.1)/r².²³
Pyrene excimer studies

Pyrene fluorescence excimer (dimer) formation was used as a parameter of the lateral diffusion in the membrane. The fluorescence of pyrene and many of its derivatives is a function of the microscopic concentration of the probe in the membrane. A membrane suspension was prepared in a deaerated 0.25 M sucrose/1 mM EDTA (pH-7.0) and 2 µl of pyrene were added from a stock solution (5 µM) made in acetone to the membrane suspension and stirred for 1 hour at 25 ºC. Final concentration of pyrene was set around 0.005 µM. Thereafter excimer and monomer intensity were measured at excitation wavelength of 320 nm and monomer emission (M) of 397 nm and excimer emission (E) of 472 nm using Perkin Elmer Luminescence spectrometer LS55. The ratio of these two fluorescence intensities, E/M is directly proportional to the pyrene concentration in the membrane hydrocarbon core as defined by: E/M = [pyrene] TK/η, where T is absolute temperature, k is the Boltzmann constant (1.38062 X 10⁻²³ J/K), and η is the viscosity.

Histological studies

Formalin fixed tissue sections (jejunum) in paraffin were dewaxed in xylene, hydrated using decreasing percentage of alcohols and brought to water. The slides were then stained with haematoxylin, counter stained with eosin and finally mounted in DPX for analysis in a light microscope.

Scanning Electron Microscopy (SEM) Study

The intestine was opened in the jejunum portion and the epithelium exposed, fixed on hard sheet in 25% glutaraldehyde phosphate buffer (pH-7.4). The fixed epithelium was dehydrated with ascending series of acetone and treated with amyl acetate (100%). The samples were subjected to critical point drying, coated with gold palladium (Fine coat ion sputter JFC-1100) material and viewed in a scanning electron microscope (JSM-6100, Jeol Japan, Scanning Electron Microscope). Different images of intestinal epithelium for treated and control were viewed and recorded.

Statistical analysis

Statistical analysis of the data was performed by analysis of variances (one way ANOVA) following one way ANOVA post-Hoc test using least significance difference (LSD).

Results

The weight changes profile showed a linear growth in the animal body weight during the six weeks treatment schedule. No significant change in the body weights were observed between the control and the treated animals as shown in figure 1.

Table I demonstrated the activity of the four different intestinal marker enzymes viz: alkaline phosphatase, sucrase, lactase and maltase in the jejunum sec-

<table>
<thead>
<tr>
<th>Enzyme assayed</th>
<th>Homogenate</th>
<th>BBM</th>
<th>Fold Purification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkaline Phosphatase</td>
<td>0.64 ± 0.21</td>
<td>8.13 ± 0.34</td>
<td>12.68</td>
</tr>
<tr>
<td>Sucrase</td>
<td>0.24 ± 0.08</td>
<td>3.12 ± 0.31</td>
<td>12.79</td>
</tr>
<tr>
<td>Lactase</td>
<td>0.05 ± 0.02</td>
<td>0.62 ± 0.04</td>
<td>11.55</td>
</tr>
<tr>
<td>Maltase</td>
<td>0.35 ± 0.08</td>
<td>4.54 ± 0.30</td>
<td>13.10</td>
</tr>
</tbody>
</table>

Values are mean ± SD of 8-10 independent observations.
A highly significant decrease was observed in the activities of alkaline phosphatase, sucrase, lactase, and maltase in DMH and aspirin treated groups when compared with the controls, however, the celecoxib and etoricoxib treatment showed a significant increase.

A highly significant decrease in total lipid content was observed (table III) in all the treatments when compared with the control and also with the DMH treated group. Similar trend was observed in cholesterol and the ganglioside-sialic acid (GSA) level when compared with the control. However, in comparison to DMH treatment only etoricoxib treated groups were found to be decreased in both cholesterol and GSA levels. Phospholipid content was found to be significantly decreased in all the treatments except the celecoxib treated group which shows a non-significant alteration.

Table IV shows that the different treatments produced significant alterations in fluorescence studies which include related parameters like fluorescence polarization, fluorescence anisotropy and order parameter. DMH treated group showed a fairly significant increase in fluorescence polarization whereas a significant decrease in fluorescence anisotropy was observed.

### Table II

**Effect of DMH, aspirin, celecoxib, and etoricoxib on intestinal marker enzymes**

<table>
<thead>
<tr>
<th>Enzyme assayed (µmoles/mg protein)</th>
<th>Groups</th>
<th>Homogenate</th>
<th>BBM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.64 ± 0.21</td>
<td>8.13 ± 0.34</td>
<td></td>
</tr>
<tr>
<td>DMH</td>
<td>0.42 ± 0.19</td>
<td>4.07 ± 0.34***</td>
<td></td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>0.49 ± 0.18</td>
<td>5.76 ± 0.36***</td>
<td></td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>0.93 ± 0.42*</td>
<td>9.58 ± 0.79***</td>
<td></td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>1.07 ± 0.21*</td>
<td>12.23 ± 0.65***</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.24 ± 0.08</td>
<td>3.12 ± 0.31</td>
<td></td>
</tr>
<tr>
<td>DMH</td>
<td>0.28 ± 0.29</td>
<td>2.42 ± 0.23***</td>
<td></td>
</tr>
<tr>
<td>Sucrese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>0.17 ± 0.05</td>
<td>2.03 ± 0.12***</td>
<td></td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>0.41 ± 0.11</td>
<td>3.75 ± 0.23***</td>
<td></td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>0.39 ± 0.14</td>
<td>3.73 ± 0.23***</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.05 ± 0.02</td>
<td>0.62 ± 0.04</td>
<td></td>
</tr>
<tr>
<td>DMH</td>
<td>0.04 ± 0.02</td>
<td>0.40 ± 0.02***</td>
<td></td>
</tr>
<tr>
<td>Lactase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>0.04 ± 0.01</td>
<td>0.48 ± 0.04**</td>
<td></td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>0.10 ± 0.03*</td>
<td>1.09 ± 0.14***</td>
<td></td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>0.10 ± 0.03*</td>
<td>1.17 ± 0.10***</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.35 ± 0.08</td>
<td>4.54 ± 0.30</td>
<td></td>
</tr>
<tr>
<td>DMH</td>
<td>0.23 ± 0.12</td>
<td>2.63 ± 0.22***</td>
<td></td>
</tr>
<tr>
<td>Maltase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>0.29 ± 0.0924</td>
<td>3.51 ± 0.23***</td>
<td></td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>0.47 ± 0.06**</td>
<td>5.57 ± 0.31***</td>
<td></td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>0.65 ± 0.09*</td>
<td>7.86 ± 0.75***</td>
<td></td>
</tr>
</tbody>
</table>

Values are mean ± S.D. of 8-10 independent observations.

*p < 0.05; **p < 0.01; ***p < 0.001 w.r.t. control.

*p < 0.05; **p < 0.001 w.r.t. DMH treated group.

### Table III

**Effect of aspirin, celecoxib and etoricoxib on lipids profile during DMH treatment of 6 weeks**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Total lipids (mg/g tissue)</th>
<th>Cholesterol (mg/g tissue)</th>
<th>Phospholipids (mg/g tissue)</th>
<th>Gangliosidesialic acid (GSA) (nmoles/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.24 ± 0.24</td>
<td>1.70 ± 0.15</td>
<td>2.51 ± 0.17</td>
<td>6.37 ± 0.68</td>
</tr>
<tr>
<td>DMH</td>
<td>3.56 ± 0.29***</td>
<td>0.93 ± 0.09***</td>
<td>1.39 ± 0.16***</td>
<td>2.6 ± 0.28***</td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>2.05 ± 0.005***</td>
<td>0.79 ± 0.08**</td>
<td>0.76 ± 0.09***</td>
<td>2.1 ± 0.20***</td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>4.62 ± 0.15***</td>
<td>1.07 ± 0.09***</td>
<td>2.77 ± 0.22***</td>
<td>2.2 ± 0.24***</td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>2.08 ± 0.01***</td>
<td>0.61 ± 0.07***</td>
<td>1.19 ± 0.11***</td>
<td>1.9 ± 0.18**</td>
</tr>
</tbody>
</table>

Values are mean ± SD of 8-10 independent observations.

*p < 0.01; **p < 0.001: treatments w.r.t. control.

*p < 0.05; **p < 0.001: treatments w.r.t. DMH.
significant increase was seen in fluorescence anisotropy. Aspirin and celecoxib treated group showed a fairly significant increase in fluorescence polarization and anisotropy value. In comparison to the DMH treatment, no significant change was found in fluorescence polarization parameter and fluorescence anisotropy value in aspirin and celecoxib treatment. In etoricoxib treated group no change was observed in fluorescence polarization and anisotropy value upto an extent of significant level. All the treatments produced no significant alterations in order parameter value.

DPH fluorescence intensity spectra (fig. 2) were recorded for the possible effects of different treatments on intestinal BBM using $\lambda_{\text{exc}}$ 365 nm and $\lambda_{\text{em}}$ 430 nm. The fluorescence intensity was found to be maximum in control BBM. DMH treatment in the BBM showed a major drop in the fluorescence intensity whereas DMH + aspirin and DMH + celecoxib treated BBMs resulted in lesser decrease in fluorescence intensity, while etoricoxib treated BBM showing the peak corresponding to least fluorescence intensity.

Table V shows the effect of pyrene excimer formation on the membrane microviscosity. In comparison to control group all the three treated groups such as DMH, aspirin, and celecoxib showed a highly significant decrease in the microviscosity of membrane, whereas in case of etoricoxib treated group, no significant change was seen.

Histological observations were recorded following H/E staining of the paraffin embedded small intestinal tissue sections after the six weeks of treatment duration at 250X magnification. In control (fig. 3a), the structural organization of intestinal villi was found to be conspicuous with extensive brush border along with the presence of columnar absorptive cells. Figure 3b shows the effects of DMH where the microvillus tip showed the diffused goblet cells present along the tip and also the slightly deformation of the striated brush border membrane. In the DMH + aspirin treated group (fig. 3c), marked disarrangement in the structural details of intestinal histoarchitecture was observed. The striated brush border was severely damaged and the goblet cells were found to be in lesser number. In figure 3d the celecoxib treatment along with the DMH administration, lesser damage was observed in the structural details in comparison to the DMH + aspirin treatment. The villus tip illustrated the numerous columnar absorptive cells all along the brush border indicating the normal cellular organization. Figure 3e shows the effect of etoricoxib treatment, where the normal structural organization was observed. The conspicuous striated brush border along with the numerous scattered goblet cells was also seen.

In scanning electron microscopic study the normal surface of small intestine epithelium is depicted in figure 4, showing the smooth texture of the epithelial cells, microvilli and the depressions in between the microvillus surface. Between the flattened cells, few depressions are also observed. Villi association with the overlined lymphoid nodules were found to be much larger than the surrounding absorptive cells.

In DMH treated intestine numerous patches of abundant loosely packed villi were found, which were much broader than those composing the brush border surrounding cells. It also showed that in the DMH +

### Table IV

<table>
<thead>
<tr>
<th>Groups</th>
<th>Polarization (p)</th>
<th>Anisotropy (r)</th>
<th>Order parameter (S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.42 ± 0.01</td>
<td>0.32 ± 0.001</td>
<td>0.95 ± 0.003</td>
</tr>
<tr>
<td>DMH</td>
<td>0.44 ± 0.003*</td>
<td>0.34 ± 0.006*</td>
<td>1.10 ± 0.12</td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>0.43 ± 0.003*</td>
<td>0.33 ± 0.001*</td>
<td>1.09 ± 0.12</td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>0.45 ± 0.004**</td>
<td>0.35 ± 0.002**</td>
<td>1.00 ± 0.002</td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>0.43 ± 0.0004</td>
<td>0.34 ± 0.001**</td>
<td>0.97 ± 0.002</td>
</tr>
</tbody>
</table>

Values are mean ± SD of 8-10 independent observations.

*p < 0.05; **p < 0.01; ***p < 0.001: treatments w.r.t. control.

*p < 0.05: treatments w.r.t. DMH.
aspirin treatment, large numbers of flattened cells were found having less smooth surface in comparison to the DMH treated sample. Besides, loosely packed microvilli were seen in lesser number. Flattened cells were found to be containing more of the villus cells with numerous folds as shown in the DMH + celecoxib treatment. Loosely packed microvilli were found in scanty number and the cell surface found to be comparatively smooth. In DMH + etoricoxib, the intestinal folds were found to be markedly increased and various patches of border microvilli found all over the flattened cells.

Discussion

The present work was carried out to study the effects of aspirin, celecoxib and etoricoxib on the activities of intestinal enzymes, and lipid profile of the small intestine of DMH treated rat. In order to see the changes in the membrane fluidity by different drug treatments, fluorescence with DPH and pyrene excimer studies were done in the BBM. Histopathological (H/E staining) studies were also performed.

The mucosa and BBM of the gastrointestinal tract, called the GI barrier, protects the intestinal lumen from the toxins and comes in direct contact with the material present in the intestine and mostly affected by the carcinogenic drugs. DMH is intestine specific pro-carcinogen, which is metabolically activated in the liver and is delivered to the intestine through the bloodstream or through bile in the form of glucuronide conjugates. In the present study, results showed significant variations in the activities of intestinal enzymes in different treatments. The decrease in the activities of intestinal disaccharidases and alkaline phosphatase was noticed in the animals treated with DMH. In treatment 3 animals (DMH + aspirin), a slight increase was noticed in the activities of the intestinal enzymes. Stimulation of the activities by aspirin treatment may suggest its anti-carcinogenic effect. Similarly, significantly high increase in the activities of all the enzymes

<table>
<thead>
<tr>
<th>Groups</th>
<th>E</th>
<th>M</th>
<th>E/M</th>
<th>Microviscosity (η)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>123.94 ± 0.30</td>
<td>417.45 ± 1.06</td>
<td>0.30 ± 0.0013</td>
<td>6.34 ± 0.03</td>
</tr>
<tr>
<td>DMH</td>
<td>83.22 ± 0.34</td>
<td>269.91 ± 0.54</td>
<td>0.31 ± 0.0009</td>
<td>6.11 ± 0.02***</td>
</tr>
<tr>
<td>DMH + Aspirin</td>
<td>146.97 ± 0.22</td>
<td>465.65 ± 0.99</td>
<td>0.31 ± 0.0008</td>
<td>5.97 ± 0.015***</td>
</tr>
<tr>
<td>DMH + Celecoxib</td>
<td>78.60 ± 0.13</td>
<td>254.63 ± 0.16</td>
<td>0.31 ± 0.0005</td>
<td>6.10 ± 0.010***</td>
</tr>
<tr>
<td>DMH + Etoricoxib</td>
<td>73.60 ± 0.05</td>
<td>248.49 ± 0.87</td>
<td>0.29 ± 0.0010</td>
<td>6.36 ± 0.0231***</td>
</tr>
</tbody>
</table>

Values are mean ± SD of 8-10 independent observations.
*** p < 0.001: treatments w.r.t. control.
### p < 0.001: treatments w.r.t. DMH.

![Fig. 3.—The effects of various treatments on villi structure of small intestine (LS) H & E 250 X. Micrograph of control. a) of small intestine showing the normal histoarchitecture of villous. DMH treatment; b) showing the numerous goblet cells along the villi and the damaged surface. DMH + aspirin treatment. c) showing the degradation of brush border and less number of goblet cells. The epithelial cells are pycnotic. DMH + celecoxib treatment. d) showing the normal morphology of columnar epithelium cells along the brush border. DMH + etoricoxib treatment and e) showing normal striated brush border with interspersed goblet cells.](image-url)
of coxib class of NSAIDs may also suggest the anticarcinogenic properties of these drugs possibly mediated through the prostaglandins. It has been reported earlier that the PGE\(_2\) concentration was higher in human colorectal tumor than in the surrounding normal tissue\(^{29,30}\) and NSAIDs are known to prevent the formation of PGE\(_2\).\(^{31}\)

Alterations in the lipid or protein composition may change the membrane fluidity, which is determined by lipid-protein interactions and in membrane fluidity is directly linked with membrane functions.\(^{32}\) Lipid profile and membrane fluidity has been observed to be altered in various pathophysiological conditions, and therefore, is an important index of cellular integrity. An increase in lipid content may also indicate an increase in fluidity across the intestinal membrane.\(^{33}\) However, in the present study, a decrease in total lipid content is seen in all the treated groups, which leads to decrease in membrane fluidity. Changes in the membrane phospholipid head group composition as well as the fatty acids can affect the membrane bound enzymes and the permeability of the membrane to ions.\(^{34}\) Increased phospholipid content in intestinal BBM under the effect of NSAIDs is supported by the fact that NSAIDs also increase membrane fluidity.\(^{35}\) Also, increased phospholipid content makes the membrane more susceptible to peroxidation-induced damages as are some of the hepatotoxic effects of NSAIDs. In the present work phospholipid content was found to be decreased in all the treatment groups which results in less membrane fluidity and also making the membrane less susceptible to peroxidation damage. Cholesterol content was also decreased in all of the treatment groups which shows that NSAIDs increase membrane fluidity as cholesterol being a rigid molecule having a cyclopentane ring structure helps in giving some order to the membrane and thereby regulate the fluidity. In a previous study Ghosh and Mukherjee\(^{11}\) reported that decrease in cholesterol:phospholipid ratio in the intestinal BBM indicates an increase in fluidity. Ganglioside level in membrane reflects a variety of cell surface events mediated by specific interactions between the carbohydrate moiety and some external ligand e.g. Ca\(^{2+}\).\(^{36}\) In the present study ganglioside composition shows a highly significant decrease in all the treatment groups. Some studies have focused on the role of gangliosides in regulating membrane viscosity showing that gangliosides, potentially increased the viscosity when introduced into the unilamellar vesicles of phosphatidyl choline.\(^{37}\)

The term lipid fluidity may refer to the relative motional freedom of the lipid molecules or substituents there off in the membrane lipid bilayer.\(^{38}\) An exact determination of lipid fluidity is difficult to achieve because of the fact that different types of molecular motion contribute to the overall membrane fluidity.
Thus, the lipid fluidity includes different types of motion e.g., rotational or lateral diffusion of molecules in an array. Here, in the present study, the rotational diffusion has been studied by DPH fluorescence. The particular usefulness of this method stems from the fact that polarization of the fluorescence of a molecule depends upon the rate of rotation where binding of a fluorophore to biological macromolecule or membrane can be monitored by an increase in the polarization of fluorescence. 

Similarly, since the rotational rate depends on the resistance offered by the microenvironment to the motion of the probe, fluorescence polarization provides an estimate of the environmental resistance which is interpretable as an apparent microviscosity and thereby as a measure of fluidity.

Lateral diffusion has been measured by the excimer formation of pyrene. In the present study, DMH, aspirin and celecoxib treated groups showed an increase in E/M ratios as compared to the control group. However, this increase is more prominent in case of aspirin treated animals. The increased value of E/M ratio leads to a decrease in the microviscosity, which in turn leads to elevation in membrane fluidity, the increased E/M ratio or increased lateral diffusion of the probe i.e., pyrene in the membrane might have resulted due to partial lipid removal and more motional freedom of the probe in the hydrocarbon phase. This has been reported earlier that increased excimer formation is indicative of enhanced fluidity of the membrane and the enhanced translational or lateral mobility of the probe in the bilayer. However, in etoricoxib treated group, an increase was observed in the microviscosity, which in turn leads to decrease in membrane fluidity, while decreased fluidity may be due to decreased diffusion of pyrene in the membrane.

Histologically, the deformation of the striated brush border membrane following the DMH treatment may be attributed to the inflammatory signs as a result of DMH action. Following the various NSAIDs treatments, the villus structure was found to be severely damaged in DMH + aspirin treatment while celecoxib showed less damage and etoricoxib treatment resulted in normal histological structure of the villi. The disarrangement of the villus surface in case of DMH + aspirin may be attributed to the non specific COX-1 inhibition by aspirin as COX-1 is essentially required for maintaining the structural integrity of the membrane cells. This observation was further confirmed by the observation that the COX-2 selective NSAIDs, celecoxib and etoricoxib have resulted in lesser or no damage, respectively, to the intestinal surface. The histological observation from the present study clearly indicates the inflammatory signs after DMH treatment and after there, maintaining the normal histoarchitecture of the small intestine following the treatments with the “coxibs”.

Scanning electron microscopic observations suggest certain important alterations in the surface morphology during the various treatments. SEM photomicrographs following DMH and DMH + NSAIDs treatment resulted in irregular surface morphology in the DMH treated epithelium. The patches of broader and loosely packed microvilli were observed in almost all the groups, with DMH group showing it in more abundance. Such cells exhibiting loosely packed broader microvilli are the cell which are normally associated with lymphoid nodules and therefore suggests inflammatory response.

In conclusion, the administration of a procarcinogenic agent, DMH, has been observed to cause oxidative and inflammatory changes in the intestinal epithelium and is corrected by the non-steroidal anti-inflammatory drugs, such as aspirin, celecoxib and etoricoxib which may suggest an effective chemopreventive action of these drugs in intestinal carcinogenesis.

Acknowledgement

Financial assistance from the University Grants Commission-Special Assistance Programme [F.3/13/2004 (SAP-II)] is gratefully acknowledged.

References